Anthony J. Recupero, the President of Commercial Operations at SI-BONE, Inc. (NASDAQ:SIBN), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transactions, dated January 2, 2025, involved the sale of 3,670 shares at an average price range of $13.8832 to $13.9155 per share, totaling approximately $51,014. SI-BONE, with a market capitalization of $594 million, has demonstrated strong revenue growth of 19% over the last twelve months and maintains a healthy balance sheet with more cash than debt. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. After these transactions, Recupero retains direct ownership of 222,814 shares of SI-BONE's common stock. The company maintains exceptional liquidity with a current ratio of 8.25, and InvestingPro subscribers can access additional insights through comprehensive Pro Research Reports, which provide detailed analysis of the company's financial health and growth prospects.
In other recent news, Piper Sandler analysts expressed optimism for several healthcare companies, including ATEC, ATRC, KIDS, FNA, and SIBN, in anticipation of a major investor conference. The analysts anticipate positive fiscal year outlooks and potential upside for consensus numbers. SI-BONE, a medical device company, reported a 19% increase in worldwide revenue to $40.3 million in its Q3 earnings, largely driven by an 18% rise in U.S. sales. Needham reiterated its Buy rating on SI-BONE, suggesting the recent dip in share price presents a buying opportunity.
Procept BioRobotics initiated a public offering of common stock valued at $175 million, with BofA Securities, and Morgan Stanley (NYSE:MS) serving as the joint book-running managers. The company reported robust revenue growth of 66% in the third quarter, totaling approximately $58.4 million. Analysts from Morgan Stanley initiated coverage on Procept BioRobotics with an Overweight rating, while Jefferies maintains a Hold rating and Truist Securities maintained a Buy rating.
These are recent developments that highlight the continued growth and potential of Procept BioRobotics and SI-BONE in their respective market sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.